Biomedicines, 2024-01, Vol.12 (1), p.179
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
- Ist Teil von
- Biomedicines, 2024-01, Vol.12 (1), p.179
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2024
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Pertuzumab and trastuzumab have been shown to improve the outcomes of patients with metastatic breast cancer, with a rate of left ventricular dysfunction of approximately 6%. We report the case of a postmenopausal woman who presented with Takotsubo syndrome during maintenance therapy with pertuzumab and trastuzumab, in association with fulvestrant (an anti-estrogen) and denosumab. After normalization of cardiac function, therapy with pertuzumab and trastuzumab was resumed in the absence of new cardiac toxicity. We report the first clinical case of Takotsubo syndrome during double anti-HER2 blockade in association with an antiestrogen. Furthermore, we show how anti-HER2 therapy can be safely resumed after the detection of Takotsubo syndrome.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2227-9059eISSN: 2227-9059DOI: 10.3390/biomedicines12010179Titel-ID: cdi_doaj_primary_oai_doaj_org_article_da21180e27684879bf526e1726daac42
- Format
- –
- Schlagworte
- Antiestrogens, Antimitotic agents, Antineoplastic agents, Biomarkers, Breast cancer, Cancer therapies, cardiac toxicity, Cardiomyopathy, Cardiotoxicity, Care and treatment, Chemotherapy, Cohort analysis, denosumab, Edema, Ejection fraction, Electrocardiography, ErbB-2 protein, Estrogen, Estrogens, Fulvestrant, Heart, Ischemia, Kinases, Medical imaging, Medical prognosis, Metastases, Metastasis, Monoclonal antibodies, Patients, pertuzumab, Post-menopause, Postmenopausal women, Takotsubo syndrome, Toxicity, Trastuzumab, Ventricle